| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
Artificial intelligence (AI) in the medical imaging industry plays an important role in improving the accuracy of diagnosis and patient outcomes. AI can help analyze medical images such as X-ray, MRI, CT scan more quickly and accurately. Helping doctors to detect abnormalities from the early stage and plan treatment effectively Leading to more accurate diagnosis and better results for patients |
This answer is based on general knowledge about the role of AI in medicine and the medical imaging industry. Which is widely accepted and supported by research today that AI helps increase the efficiency and accuracy of disease diagnosis and actually improve patient treatment outcomes. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Reduces the speed of diagnosing |
|
The Question About The Main Benefits Of AI In Radiology Mentioned In The Article. The Option "Reduces The Speed Of Diagnosis" (Reduces The Speed Of Diagnosis) Is A Benefit That Is Consistent With The Use Of AI In Medicine. Especially In The Field Of Radiology, Which AI Can Help Speed Up The Process Of Analyzing Medical Images And Help Speed Up The Diagnosis. |
"Increases The Need For Radiologists" - AI is often seen as a supplement to the work of radiologists rather than directly increasing demand.
"Helps In Scheduling Patient Visits" - Although AI plays a role in managing the system, but it is not the main benefit in radiology.
"Acts As A Second Medical Opinion" (Acts As A Second Medical Opinion) - AI May Provide Information To Support The Diagnosis. But In General, A Second Medical Opinion Often Comes From Another Doctor.
"Increases The Cost Of Medical Imaging" (Increases The Cost Of Medical Imaging) - AI Tends To Help Reduce Costs In The Long Run Or Make The Process More Efficient. Rather Than Increasing The Cost Directly |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
Knowledge and understanding of AI (AI literacy) generally refers to the understanding and knowledge of AI technology, which covers the working principles, implementation, social and ethical impacts associated with AI. Having these basic knowledge will help people to effectively utilize AI and realize the limitations and potential risks. |
The Ability To Repair AI Machines:
It is a matter of specific technical skills, not overall knowledge.
The History Of AI Development:
It is part of AI knowledge, but not all of "AI literacy".
Legal Knowledge About AI Usage:
It is a specialized knowledge of laws related to the use of AI.
Financial Management Of AI Systems:
It is a specialized knowledge about the financial management of the AI system. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
The color of the AI machine is not a factor directly related to the acceptance or ability of AI to work in a medical or healthcare context. |
From The Options Provided In The Picture, All Other Factors Such As Trust In AI Systems (Trust In AI Systems), Integration Of AI With Existing Workflows (Integrating AI Into Existing Workflows), System Understanding (System Understanding) And Technology Receptiveness (Technology Exposure) Are All Important Factors That Affect The Acceptance Of AI In Health Care. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
This question asks about the role of social influence that affects the adoption of AI in health care according to the article. Although the article does not provide direct details in the picture But in general, social influence often affects the decision of medical personnel to use AI in medical facilities, such as recognizing the benefits of colleagues. Confidence in widely accepted technology Or organizational policies and practices that promote the use of AI |
Social influence theory describes how a person's thoughts, feelings, and behaviors are influenced by others or social groups. In the context of adopting AI in health care, social influence can come from colleagues, other health professionals, patients, or even the public, which may affect the decision of medical personnel to implement AI. The most accurate option is "Affects Healthcare Professionals' Decisions To Use AI" because it reflects the direct impact of social influence on the decision of medical personnel to use AI in health care. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
This is a perceived threat to the use of AI in health care. Because there is a concern that AI may come into some work that is currently done by medical personnel. Causing concern about replacing job positions or reducing the role of humans in the health care sector |
Social and Occupational Transformation Theories:
Explain the impact of new technologies that change the way of working and human roles in organizations and society as a whole. In this case, AI may replace or change the role of medical personnel.
Ethical principles in the use of artificial intelligence (AI Ethics Principles):
Especially the principles related to accountability (Accountability), transparency (Transparency), and fairness (Fairness) in the use of AI in contexts that affect human life, such as patient-doctor interaction or medical decision-making.
Human-Technology Interaction Theories:
This may consider the impact of using AI that may reduce direct interaction between patients and doctors, which is an important part of holistic health care. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
Human-centred AI focuses on aligning AI technologies with the real needs, workflows, and concerns of medical professionals. This makes AI systems more intuitive, trustworthy, and ethically acceptable in clinical settings. |
This is supported by the principle of human-centered design in healthcare innovation. According to research in AI ethics and implementation science, increasing acceptance among professionals requires designing systems that enhance—not replace—human roles, ensure transparency, and support decision-making rather than control it. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The system usage category usually refers to how well an AI system fits into existing clinical workflows, its practical utility (value proposition), and how seamlessly it can be used by healthcare professionals in their daily routines.
|
This aligns with technology acceptance models (e.g., TAM, UTAUT) and implementation science, which emphasize that for a system to be adopted, it must offer clear benefits, be easy to integrate, and enhance rather than disrupt existing practices. These factors influence perceived usefulness and ease of use—key determinants of acceptability. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Ethicality plays a key role in how healthcare professionals perceive AI. If an AI system aligns with medical ethics—such as patient safety, confidentiality, and fairness—it is more likely to be accepted and trusted by medical staff. |
According to frameworks like the Technology Acceptance Model (TAM) and literature on AI ethics in medicine, compatibility with professional and ethical values (e.g. autonomy, beneficence, non-maleficence) is a strong predictor of whether healthcare workers will adopt AI tools. Ethical concerns—such as bias, transparency, and accountability—must be addressed for AI to be deemed acceptable in clinical practice.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The article emphasizes that understanding how users (e.g. doctors, nurses) interact with AI systems—and how well these systems fit into existing clinical workflows—is crucial for studying and improving AI acceptability. This includes analyzing usability, transparency, trust, and seamless integration into daily medical practices. |
This aligns with human-centered design, implementation science, and user-centered evaluation frameworks. These approaches stress the importance of studying AI in real-world contexts, focusing on how it affects clinical decision-making, workload, and patient outcomes—rather than just technical performance or economic benefits. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
In Parkinson’s disease, the dopamine-producing neurons in the brain are damaged or lost, causing a decrease in dopamine levels. This leads to problems with movement control.
The purpose of using human embryonic stem cells is to develop and replace these lost neurons by differentiating into dopamine-producing cells. This helps restore brain function and improve the symptoms of Parkinson’s disease. |
Lindvall & Kokaia (2006) describe how stem cells can be used to replace lost neurons in neurodegenerative diseases, supporting the goal of restoring dopamine levels by replacing lost dopamine neurons. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Monkeys |
|
Non-human primates (monkeys) are often used in preclinical testing of neurological treatments like STEM-PD because their brain structure and function, especially the dopaminergic system affected in Parkinson’s disease, are more similar to humans than those of rodents or other animals. This similarity allows for a better assessment of both safety and efficacy before moving to human trials. |
The translational research model in neuroscience emphasizes using animal models that closely mimic human disease conditions for accurate preclinical evaluation. Monkeys are preferred for Parkinson’s disease research due to their comparable basal ganglia anatomy and dopamine pathways (Emborg, 2007). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
6 months |
|
Preclinical safety studies in rodents like rats often last several months to observe potential long-term toxic effects and assess the safety profile of a treatment before clinical trials. A 6-month duration is common to provide enough time to monitor chronic effects without extending unnecessarily long, balancing thoroughness and practicality. |
The toxicological evaluation framework for new therapies recommends subchronic (3–6 months) studies in rodents to detect adverse effects and assess safety for chronic human use (ICH Guideline M3(R2), 2009). This period is considered sufficient for evaluating repeated-dose toxicity and potential side effects. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
The clinical trial phase mentioned for STEM-PD combines Phase I and Phase IIa, which is common for early-stage trials of novel therapies. Phase I focuses primarily on safety and dosage, while Phase IIa starts to evaluate preliminary efficacy. Combining these phases allows researchers to efficiently assess both safety and initial therapeutic effects in a small group of patients. |
According to clinical trial design principles, Phase I/IIa trials serve as an early exploration of safety, tolerability, and preliminary efficacy in patients, bridging the gap between purely safety-focused Phase I and efficacy-focused Phase II (Fleming & DeMets, 1996). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
STEM-PD, being a cell therapy product intended for clinical use, must be manufactured under Good Manufacturing Practice (GMP)-compliant conditions to ensure product quality, safety, and consistency. GMP standards are critical in the production of advanced therapies to meet regulatory requirements and protect patient safety.
|
The regulatory framework for cell and gene therapies requires that products used in humans are produced under GMP conditions to minimize risks such as contamination, variability, or impurities (European Medicines Agency, 2017). This ensures reproducibility and compliance with quality standards necessary for clinical trials and eventual market approval. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
Safety in preclinical studies is confirmed when no harmful side effects, such as toxicity, immune reactions, or tumor formation, are observed. For STEM-PD, the absence of adverse effects and tumor formation in rats indicates that the product is safe for further development. |
According to toxicology and safety assessment principles, a key requirement before advancing to human trials is demonstrating that a therapy does not induce tumors or harmful reactions in animal models (ICH S6(R1) guideline, 2011). This confirms biocompatibility and reduces risks for clinical use. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
The key goal of STEM-PD treatment is to restore dopamine function by replacing lost neurons. In preclinical efficacy studies, a positive outcome is when transplanted cells survive, differentiate properly, and improve motor symptoms caused by Parkinson’s-like damage. Observing reversal of motor deficits indicates successful functional integration and therapeutic benefit. |
The cell replacement therapy model predicts that replacing lost dopaminergic neurons will improve motor function in Parkinson’s disease models (Lindvall & Kokaia, 2006). Functional recovery in animal models is a critical indicator before human trials. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
LMX1A and EN1 |
|
LMX1A and EN1 are transcription factors specifically expressed in midbrain dopaminergic progenitor cells. These markers are used to assess the purity of the STEM-PD cell batch because their presence indicates successful differentiation toward the desired dopaminergic neuron lineage, which is crucial for effective Parkinson’s treatment. |
In developmental neurobiology, LMX1A and EN1 are well-established markers for midbrain dopaminergic neurons. Their expression confirms that stem cells have differentiated properly into the neuronal subtype relevant for Parkinson’s disease therapy (Andersson et al., 2006). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
Growth factors like FGF8b (Fibroblast Growth Factor 8b) and SHH (Sonic Hedgehog) are critical signaling molecules during neural development. In the manufacturing of STEM-PD, these factors guide human embryonic stem cells to differentiate into specific neural progenitors, particularly midbrain dopaminergic neurons, by mimicking the developmental cues in the embryo. This process is called cell patterning. |
Developmental biology shows that FGF8b and SHH gradients regulate the regional identity of neural progenitors in the ventral midbrain, essential for generating dopaminergic neurons (Hynes et al., 1995; Ye et al., 1998). Applying these factors in vitro directs stem cells to the desired neural fate, a foundational principle in regenerative medicine. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
Parkinson’s disease primarily impairs motor function due to the loss of dopamine-producing neurons. In preclinical trials for therapies like STEM-PD, a key outcome is whether the treatment improves movement-related symptoms in animal models (e.g., rats with Parkinsonian symptoms). Recovery of motor function indicates that transplanted cells are functioning correctly—surviving, integrating, and producing dopamine. |
In neuroscience and regenerative medicine, functional recovery, especially of motor ability, is the gold standard for assessing efficacy in Parkinson’s models. Successful outcomes are often measured using behavioral tests such as amphetamine-induced rotation or limb use asymmetry in rats (Björklund & Lindvall, 2000). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|